AstraZeneca Q3 Earnings Preview: Will Cancer, Heart Drugs Fuel Continued Growth?

AstraZeneca plc (NASDAQ:AZN) is set to report its third-quarter 2024 earnings Tuesday morning, and the company's second-quarter performance hints at robust growth fueled by its oncology and cardiovascular portfolios.

What To Know: In the second quarter, AstraZeneca reported $12.94 billion in revenue, marking a 13% year-over-year increase (17% at constant currency), surpassing analysts' expectations of $12.75 billion.

This was bolstered by steady demand across its core therapeutic areas and an impressive array of high-performing drugs. Adjusted earnings per ADR (equivalent to two common shares) came in at 99 cents, in line with consensus, while adjusted EPS reached $1.98.

AstraZeneca's oncology division, which remains the largest revenue driver, saw a 15% boost ...